Adam Andrzejewski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adam Andrzejewski has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Dominika Raether
F. Ceynowa Specialist Hospital in Wejherowo, Wejherowo, Poland
5 shared publications - Alia Echtay Yarbou
Lazarski University, Warsaw, Mazovia, Poland
3 shared publications - Dominika Dutkiewicz
Independent Public Health Care Centre of the Ministry of the Interior and Administration in Gdańsk, Poland
3 shared publications - Dominika Julia Kozdroń
University Clinical Centre, Gdansk, Poland
3 shared publications - Jacek Kowalski
University Clinical Centre in Gdańsk, Poland
3 shared publications - Michalina Weronika Nieścioruk
7th Navy Hospital, Gdańsk, Poland
3 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
THE GUT–BRAIN AXIS IN AUTISM SPECTRUM DISORDER: MICROBIOTA, IMMUNE DYSREGULATION, AND THERAPEUTIC PERSPECTIVES
Background: Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by persistent difficulties in social communication, restricted and repetitive behaviors, and a high prevalence of co-occurring gastrointestinal, metabolic, and immune disturbances. Increasing evidence suggests that the gut–brain axis—a bidirectional communication network linking intestinal microbiota, immune signaling, metabolic pathways, and neural circuits—may play an important modulatory role in ASD-related neurodevelopmental processes. Scope: This review synthesizes current evidence on gut–brain axis physiology and examines how alterations in microbiota composition and function intersect with immune dysregulation, microbial metabolite signaling, and neurodevelopment in ASD. Findings from clinical studies, preclinical mechanistic research, and emerging microbiota-targeted therapeutic approaches are integrated to provide a systems-level perspective on microbiota–immune–brain interactions. Key Findings: Individuals with ASD frequently exhibit altered gut microbial diversity and composition, accompanied by functional disruptions in microbial metabolite pathways, including short-chain fatty acid and tryptophan metabolism. These changes are associated with impaired intestinal barrier integrity, systemic immune activation, neuroinflammatory signaling, and microglial dysfunction, processes that may contribute to excitatory–inhibitory imbalance and altered synaptic plasticity in the central nervous system. Microbiota-targeted interventions—such as probiotics, dietary modification, and fecal microbiota transplantation—demonstrate preliminary benefits for gastrointestinal symptoms and selected behavioral outcomes, although clinical evidence remains heterogeneous and limited. Conclusions: Current evidence supports a multifactorial model in which gut microbiota alterations act as modulatory amplifiers of neurodevelopmental vulnerability in ASD rather than as primary causal factors. Interactions among microbial metabolism, immune regulation, environmental exposures, and developmental timing appear central to this process. Future progress will depend on longitudinal, multi-omics approaches and biomarker-driven stratification to enable precision-based microbiota-targeted interventions.
- 19 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
Open AccessTHE GUT–BRAIN AXIS IN AUTISM SPECTRUM DISORDER: MICROBIOTA, IMMUNE DYSREGULATION, AND THERAPEUTIC PERSPECTIVES
Background: Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by persistent difficulties in social communication, restricted and repetitive behaviors, and a high prevalence of co-occurring gastrointestinal, metabolic, and immune disturbances. Increasing evidence suggests that the gut–brain axis—a bidirectional communication network linking intestinal microbiota, immune signaling, metabolic pathways, and neural circuits—may play an important modulatory role in ASD-related neurodevelopmental processes. Scope: This review synthesizes current evidence on gut–brain axis physiology and examines how alterations in microbiota composition and function intersect with immune dysregulation, microbial metabolite signaling, and neurodevelopment in ASD. Findings from clinical studies, preclinical mechanistic research, and emerging microbiota-targeted therapeutic approaches are integrated to provide a systems-level perspective on microbiota–immune–brain interactions. Key Findings: Individuals with ASD frequently exhibit altered gut microbial diversity and composition, accompanied by functional disruptions in microbial metabolite pathways, including short-chain fatty acid and tryptophan metabolism. These changes are associated with impaired intestinal barrier integrity, systemic immune activation, neuroinflammatory signaling, and microglial dysfunction, processes that may contribute to excitatory–inhibitory imbalance and altered synaptic plasticity in the central nervous system. Microbiota-targeted interventions—such as probiotics, dietary modification, and fecal microbiota transplantation—demonstrate preliminary benefits for gastrointestinal symptoms and selected behavioral outcomes, although clinical evidence remains heterogeneous and limited. Conclusions: Current evidence supports a multifactorial model in which gut microbiota alterations act as modulatory amplifiers of neurodevelopmental vulnerability in ASD rather than as primary causal factors. Interactions among microbial metabolism, immune regulation, environmental exposures, and developmental timing appear central to this process. Future progress will depend on longitudinal, multi-omics approaches and biomarker-driven stratification to enable precision-based microbiota-targeted interventions.
- Open Access
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
MODERN SURGICAL TECHNIQUES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW
Aims: To systematically review randomized evidence on modern minimally invasive and endoscopic techniques for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), focusing on clinical efficacy, safety, perioperative outcomes, preservation of sexual/ejaculatory function, and durability compared with TURP or sham. Methods: We conducted a systematic PubMed search (2020–2025) using predefined terms for BPH surgery and randomized controlled trials. Main findings from eligible articles were summarized. Results: The review identified 41 randomized controlled trials evaluating nine modern techniques (endoscopic enucleation, laser vaporization, Aquablation, Rezūm water vapor thermal therapy, prostatic urethral lift/PUL, transperineal laser ablation/TPLA, temporary nitinol device/iTind, drug-coated balloon/Optilume, and prostatic artery embolisation/PAE), comprising thousands of men with moderate-to-severe LUTS. Endoscopic enucleation and Aquablation showed durable, TURP-like or superior improvements in IPSS, QoL, Qmax, and PVR, particularly in large prostates (>80 mL), with better perioperative outcomes. Minimally invasive surgical therapies (MISTs) provided meaningful symptom relief and excellent preservation of sexual/ejaculatory function, while PAE had lower objective efficacy and higher reintervention rates. Serious complications were uncommon across all techniques. Conclusions: Current evidence supports these modern techniques as valuable alternatives to TURP, enabling individualized treatment based on prostate volume and patient priorities for sexual function, recovery, and durability. However, heterogeneity in follow-up duration, variable prostate-size criteria, and the limited number of large head-to-head trials restrict definitive conclusions. Further adequately powered, long-term randomized studies are needed to better define the optimal role of each modality in clinical practice.
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessMODERN SURGICAL TECHNIQUES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW
Aims: To systematically review randomized evidence on modern minimally invasive and endoscopic techniques for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), focusing on clinical efficacy, safety, perioperative outcomes, preservation of sexual/ejaculatory function, and durability compared with TURP or sham. Methods: We conducted a systematic PubMed search (2020–2025) using predefined terms for BPH surgery and randomized controlled trials. Main findings from eligible articles were summarized. Results: The review identified 41 randomized controlled trials evaluating nine modern techniques (endoscopic enucleation, laser vaporization, Aquablation, Rezūm water vapor thermal therapy, prostatic urethral lift/PUL, transperineal laser ablation/TPLA, temporary nitinol device/iTind, drug-coated balloon/Optilume, and prostatic artery embolisation/PAE), comprising thousands of men with moderate-to-severe LUTS. Endoscopic enucleation and Aquablation showed durable, TURP-like or superior improvements in IPSS, QoL, Qmax, and PVR, particularly in large prostates (>80 mL), with better perioperative outcomes. Minimally invasive surgical therapies (MISTs) provided meaningful symptom relief and excellent preservation of sexual/ejaculatory function, while PAE had lower objective efficacy and higher reintervention rates. Serious complications were uncommon across all techniques. Conclusions: Current evidence supports these modern techniques as valuable alternatives to TURP, enabling individualized treatment based on prostate volume and patient priorities for sexual function, recovery, and durability. However, heterogeneity in follow-up duration, variable prostate-size criteria, and the limited number of large head-to-head trials restrict definitive conclusions. Further adequately powered, long-term randomized studies are needed to better define the optimal role of each modality in clinical practice.
- Open Access
- 26 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
RECURRENT FEVER IN CHILDREN – DIAGNOSTIC APPROACH AND RED FLAGS FOR SERIOUS DISEASES
Recurrent fever in children represents a diagnostically challenging and clinically heterogeneous condition that extends beyond repeated exposure to common infections. While most febrile episodes in early childhood are self-limiting, a subset of children experiences recurrent episodes separated by periods of complete or near-complete well-being, necessitating careful evaluation to distinguish benign from serious underlying conditions. This review aims to synthesize the current state of knowledge regarding recurrent fever in children and to provide a clinically oriented analysis of the differential diagnosis. The specific objectives are to systematically characterize autoinflammatory, immunodeficiency-related, autoimmune, and oncologic causes; to outline a structured and evidence-based diagnostic approach; and to identify clinical red flags suggestive of a serious underlying pathology. Methods: This review is based on peer-reviewed literature on pediatric recurrent fever and periodic fever syndromes (references 1–27). Narrative and systematic reviews, clinical guidelines, and original studies were qualitatively synthesized with focus on etiology, immunopathogenesis, key clinical features, and diagnostic red flags. Results: Recurrent fever encompasses a broad spectrum of conditions, from benign periodic fever syndromes such as PFAPA to monogenic autoinflammatory diseases (FMF, TRAPS, MKD, CAPS), immunodeficiencies (CVID, cyclic neutropenia), autoimmune disorders (sJIA, SLE), and oncologic causes. Stepwise evaluation includes detailed history, physical examination, baseline and targeted laboratory testing, and genetic assessment when appropriate. Recognition of red flags—including growth retardation, persistent laboratory abnormalities, organomegaly, atypical fever patterns, severe systemic symptoms, and relevant family history—facilitates early identification of high-risk patients and guides targeted investigations. Conclusion: Early and structured assessment of children with recurrent fever, guided by clinical pattern recognition and red flags, is essential for accurate diagnosis, timely referral, and individualized management. Integration of immunopathogenic insights and practical diagnostic strategies enhances clinical decision-making and improves patient outcomes in potentially life-threatening conditions.
- 26 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
Open AccessRECURRENT FEVER IN CHILDREN – DIAGNOSTIC APPROACH AND RED FLAGS FOR SERIOUS DISEASES
Recurrent fever in children represents a diagnostically challenging and clinically heterogeneous condition that extends beyond repeated exposure to common infections. While most febrile episodes in early childhood are self-limiting, a subset of children experiences recurrent episodes separated by periods of complete or near-complete well-being, necessitating careful evaluation to distinguish benign from serious underlying conditions. This review aims to synthesize the current state of knowledge regarding recurrent fever in children and to provide a clinically oriented analysis of the differential diagnosis. The specific objectives are to systematically characterize autoinflammatory, immunodeficiency-related, autoimmune, and oncologic causes; to outline a structured and evidence-based diagnostic approach; and to identify clinical red flags suggestive of a serious underlying pathology. Methods: This review is based on peer-reviewed literature on pediatric recurrent fever and periodic fever syndromes (references 1–27). Narrative and systematic reviews, clinical guidelines, and original studies were qualitatively synthesized with focus on etiology, immunopathogenesis, key clinical features, and diagnostic red flags. Results: Recurrent fever encompasses a broad spectrum of conditions, from benign periodic fever syndromes such as PFAPA to monogenic autoinflammatory diseases (FMF, TRAPS, MKD, CAPS), immunodeficiencies (CVID, cyclic neutropenia), autoimmune disorders (sJIA, SLE), and oncologic causes. Stepwise evaluation includes detailed history, physical examination, baseline and targeted laboratory testing, and genetic assessment when appropriate. Recognition of red flags—including growth retardation, persistent laboratory abnormalities, organomegaly, atypical fever patterns, severe systemic symptoms, and relevant family history—facilitates early identification of high-risk patients and guides targeted investigations. Conclusion: Early and structured assessment of children with recurrent fever, guided by clinical pattern recognition and red flags, is essential for accurate diagnosis, timely referral, and individualized management. Integration of immunopathogenic insights and practical diagnostic strategies enhances clinical decision-making and improves patient outcomes in potentially life-threatening conditions.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
DIAGNOSIS, TREATMENT AND SOMATIC MANIFESTATION OF ENDOMETRIOSIS: AN UPDATED REVIEW
Endometriosis is a chronic gynecological condition affecting millions of women worldwide. It involves the growth of endometrial-like tissue outside the uterine cavity, which leads to significant symptoms and a marked decline in quality of life. The aim of the Study: The purpose of this work is to present the most recent knowledge on the diagnosis, treatment methods, and somatic symptoms of endometriosis. The analysis covers publications from 2020 to 2025 and focuses on evaluating current medical approaches as well as identifying areas that require further development to improve prognosis and the daily functioning of patients. Materials and Methods: A structured search of publications from 2020–2025 was conducted in the PubMed and Google Scholar databases using keywords related to diagnostic methods, therapeutic options, and the somatic and psychosomatic symptoms of endometriosis. Results: Our review highlights that while invasive laparoscopy remains the diagnostic gold standard for endometriosis, advanced imaging techniques like transvaginal ultrasound and MRI are increasingly crucial, particularly for deep infiltrative disease. Despite these tools, significant diagnostic delays persist due to non-specific symptoms and the lack of sensitive non-invasive biomarkers. Current treatments involve hormonal therapies and surgical removal of lesions, but these approaches face challenges such as side effects, recurrence risks, and complications. Crucially, endometriosis is recognized as a multisystem disorder with diverse somatic manifestations including gastrointestinal, urinary, and systemic symptoms like chronic fatigue, alongside significant mental health impacts and increased risks for conditions such as cardiovascular disease and certain cancers Conclusions: The collected data indicate that endometriosis is a multisystem disorder, and its effective management requires collaboration among specialists from various fields. Such an approach enables better tailoring of therapy and improved symptom control. A major challenge remains the long diagnostic delay, which still ranges from several to more than ten years. Advances in modern imaging techniques and the development of sensitive biomarkers may substantially shorten this period and allow earlier intervention.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessDIAGNOSIS, TREATMENT AND SOMATIC MANIFESTATION OF ENDOMETRIOSIS: AN UPDATED REVIEW
Endometriosis is a chronic gynecological condition affecting millions of women worldwide. It involves the growth of endometrial-like tissue outside the uterine cavity, which leads to significant symptoms and a marked decline in quality of life. The aim of the Study: The purpose of this work is to present the most recent knowledge on the diagnosis, treatment methods, and somatic symptoms of endometriosis. The analysis covers publications from 2020 to 2025 and focuses on evaluating current medical approaches as well as identifying areas that require further development to improve prognosis and the daily functioning of patients. Materials and Methods: A structured search of publications from 2020–2025 was conducted in the PubMed and Google Scholar databases using keywords related to diagnostic methods, therapeutic options, and the somatic and psychosomatic symptoms of endometriosis. Results: Our review highlights that while invasive laparoscopy remains the diagnostic gold standard for endometriosis, advanced imaging techniques like transvaginal ultrasound and MRI are increasingly crucial, particularly for deep infiltrative disease. Despite these tools, significant diagnostic delays persist due to non-specific symptoms and the lack of sensitive non-invasive biomarkers. Current treatments involve hormonal therapies and surgical removal of lesions, but these approaches face challenges such as side effects, recurrence risks, and complications. Crucially, endometriosis is recognized as a multisystem disorder with diverse somatic manifestations including gastrointestinal, urinary, and systemic symptoms like chronic fatigue, alongside significant mental health impacts and increased risks for conditions such as cardiovascular disease and certain cancers Conclusions: The collected data indicate that endometriosis is a multisystem disorder, and its effective management requires collaboration among specialists from various fields. Such an approach enables better tailoring of therapy and improved symptom control. A major challenge remains the long diagnostic delay, which still ranges from several to more than ten years. Advances in modern imaging techniques and the development of sensitive biomarkers may substantially shorten this period and allow earlier intervention.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
A REVIEW OF PHARMACOLOGICAL ADVANCES IN THE MANAGEMENT OF GERD, 2015-2025
Background: Gastroesophageal reflux disease (GERD) remains one of the most prevalent gastrointestinal disorders worldwide. Between 2015 and 2025, advances in understanding its multifactorial pathophysiology have driven significant changes in pharmacological management. Aim: This review summarizes key developments in GERD pathophysiology and evaluates significant pharmacological advances from 2015 to 2025, including comparative safety profiles, limitations of current therapies, and emerging treatment directions. Methods: A structured search of PubMed, Google Scholar, and major open-access databases was performed using keywords related to GERD, pathophysiology, proton pump inhibitors, P-CABs, prokinetics, neuromodulators, and novel therapies. Results: Proton pump inhibitors remain first-line therapy but show variable efficacy in non-erosive disease and refractory symptoms. Newer agents such as potassium-competitive acid blockers, modern prokinetics, alginate-based formulations, neuromodulators, and mucosal protectants offer therapeutic benefits in selected phenotypes. Comparative analyses highlight the importance of optimizing long-term PPI use and monitoring potential adverse effects. Advances in diagnostics and improved understanding of sensory and functional mechanisms have enabled more individualized treatment strategies. Conclusions: Pharmacological management of GERD has evolved substantially over the past decade, shifting toward mechanism-based and patient-specific therapy. Future progress will depend on integrating high-resolution diagnostics, refining reflux phenotypes, and developing novel treatments that target mucosal integrity, hypersensitivity, and non-acid reflux.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessA REVIEW OF PHARMACOLOGICAL ADVANCES IN THE MANAGEMENT OF GERD, 2015-2025
Background: Gastroesophageal reflux disease (GERD) remains one of the most prevalent gastrointestinal disorders worldwide. Between 2015 and 2025, advances in understanding its multifactorial pathophysiology have driven significant changes in pharmacological management. Aim: This review summarizes key developments in GERD pathophysiology and evaluates significant pharmacological advances from 2015 to 2025, including comparative safety profiles, limitations of current therapies, and emerging treatment directions. Methods: A structured search of PubMed, Google Scholar, and major open-access databases was performed using keywords related to GERD, pathophysiology, proton pump inhibitors, P-CABs, prokinetics, neuromodulators, and novel therapies. Results: Proton pump inhibitors remain first-line therapy but show variable efficacy in non-erosive disease and refractory symptoms. Newer agents such as potassium-competitive acid blockers, modern prokinetics, alginate-based formulations, neuromodulators, and mucosal protectants offer therapeutic benefits in selected phenotypes. Comparative analyses highlight the importance of optimizing long-term PPI use and monitoring potential adverse effects. Advances in diagnostics and improved understanding of sensory and functional mechanisms have enabled more individualized treatment strategies. Conclusions: Pharmacological management of GERD has evolved substantially over the past decade, shifting toward mechanism-based and patient-specific therapy. Future progress will depend on integrating high-resolution diagnostics, refining reflux phenotypes, and developing novel treatments that target mucosal integrity, hypersensitivity, and non-acid reflux.